342 Long-Term Follow-up of 54 Cases of Recurrent Glioblastoma Treated with Magnetic Resonance-Guided Laser Interstitial Thermal Therapy

Abstract

INTRODUCTION: Magnetic resonance guided laser-induced thermal therapy (MRgLITT) is a novel minimally invasive procedural treatment for progressive cerebral lesions and cerebral edema related to post-radiation treatment effect. METHODS: We conducted a single-center retrospective study of pre-operative imaging, clinical characteristics and survival outcomes of 54 patients with previously treated (WHO Grade IV) between January 2013 to December 2020. RESULTS: The average age of patients was 58.7 ± 12.0 years. Patients underwent MRgLITT a median time of 21.6 ± 23.7 months from original diagnosis. 20% (n = 11) of patients had previous history of stereotactic radiosurgery, 61% (n = 33) intensity-modulated radiation therapy, and 80% (n = 43) chemotherapy. There was an average of 1.2 ± 0.7 prior surgical resections before MRgLITT was performed. 41% (n = 22) of patients were on dexamethasone at the time of treatment. The median pre-operative enhancing lesion volume on T1 gadolinium-enhanced magnetic resonance imaging (MRI) was 9.7 cm3 (standard error [SE], 2.0 cm3) and 27.0 cm3 (SE, 5.6 cm3) on T2 fluid-attenuated inversion recovery MRI. The pathology of the biopsies taken during MRgLITT confirmed tumor recurrence in 61% (n = 33) of patients, and treatment effect or reactive changes in 37% (n = 20) of patients. 67% (n = 28) experienced radiographic evidence of progression of the previously treated lesion, while 21% (n =9) and 12% (n = 5) experienced progression of a new lesion or both, respectively. Progression-free survival after MRgLITT was 3.5 months (standard error [SE], 0.6; 95% CI, 2.4-4.6). At the time of the study, 78% (n = 42) of patients were deceased. Mean overall survival time was 29.9 months (SE, 4.3; 95% CI, 21.4-38.3). Mean survival time after MRgLITT was 8.3 months (SE, 1.2; 95% CI, 5.9-10.6. Of the 12 remaining living patients, 36% (n = 4) had a decline in their clinical status at the time of last follow up, while 64% (n = 7) and 9% (n = 1) were stable or improved, respectively. Patients were followed for a mean time interval of 9.25 ± 12.2 months from MRgLITT. CONCLUSION: MRgLITT may be a viable, minimally invasive option for patients with glioblastoma but is associated with relatively short post-treatment progression-free survival.